Plain-English translation of NCT07261644 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new injectable medication called 608 to see if it can help adults with ankylosing spondylitis — a type of inflammatory spine disease — who haven't responded well to standard pain relievers. Researchers want to understand whether this treatment works better than a placebo (inactive injection) and whether it is safe to use over time. The trial will follow participants for up to 60 weeks to measure how much the medication helps with symptoms and what side effects, if any, occur.
Many people with ankylosing spondylitis don't get enough relief from standard anti-inflammatory drugs or can't take them due to side effects or allergies. This trial exists to test whether this new injectable medication offers a better treatment option for those patients.
You likely qualify if…
You likely don't qualify if…
You would receive either the new medication 608 or a placebo as a subcutaneous (under-the-skin) injection. Neither you nor the researchers would know which one you're getting at first. You would visit the clinic multiple times over 60 weeks for check-ups, blood tests, and assessments of how you're feeling. The main focus will be on measuring your symptoms and any side effects at week 16, with continued monitoring for safety through week 60.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Enrollment target
~500 participants
Started
November 2025
Primary completion
January 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Qing hong Zhou
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.